{"product_id":"passagebio-business-model-canvas","title":"Passage Bio Business Model Canvas","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePassage Bio Business Model Canvas: Rare Disease Gene Therapy Strategy, Partnerships \u0026amp; Commercial Outlook\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eExplore Passage Bio's business model with a focused Business Model Canvas-see how its AAV-based gene therapy platform, strategic collaborations, and rare CNS disease focus shape value creation, customer relevance, and commercialization logic; download the full Word\/Excel canvas for a clear section-by-section view, financial context, and practical insights for research, benchmarking, or strategic planning.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eartnerships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eUniversity of Pennsylvania Gene Therapy Program\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe University of Pennsylvania Gene Therapy Program collaboration, led by Dr. James Wilson, gives Passage Bio access to AAV (adeno-associated virus) platforms and IP that accelerated its pipeline; as of Dec 31, 2025 Passage Bio reported R\u0026amp;D partnerships contributing to 38% of preclinical program funding and reduced early-stage spend by an estimated $24M through shared trials and licensing terms.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eContract Manufacturing Organizations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePassage Bio uses specialized contract manufacturing organizations (CMOs) to produce AAV viral vectors for clinical programs, with partners scaling from lab to cGMP batches to meet FDA standards; in 2024 CMOs handled \u0026gt;90% of vector production industry-wide and reduce capital spend by millions. Maintaining CMO ties secures trial supplies and will be critical for global commercial supply-chain stability as Passage Bio advances toward late-stage studies and potential 2026+ launches.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePatient Advocacy Groups\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eWorking with groups like the Association for Frontotemporal Degeneration helps Passage Bio refine patient needs and cut recruitment time-FTD advocacy networks supported ~40% of patients in recent U.S. rare‑disease trial enrollments, crucial when eligible pools number in the low hundreds. These partners shape endpoints, boost community trust, and strengthen value claims to payers and investors by aligning trials with real‑world patient priorities.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical Research Organizations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePassage Bio partners with global clinical research organizations (CROs) to run multi-center gene therapy trials, outsourcing site monitoring, data collection, and regional regulatory compliance so the company stays lean while ensuring trial quality.\u003c\/p\u003e\n\u003cp\u003eUsing CROs lets Passage Bio scale across programs-by end-2024 CRO-managed trials supported ~40 sites across 10 countries, cutting internal clinical headcount and saving an estimated $6-9M per Phase 2 program.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCROs manage site monitoring, data capture, regulatory filings\u003c\/li\u003e\n\u003cli\u003eSupports ~40 sites in 10 countries (end-2024)\u003c\/li\u003e\n\u003cli\u003eSaves ~$6-9M per Phase 2 program via outsourcing\u003c\/li\u003e\n\u003cli\u003eEnables simultaneous programs at different stages\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory Agencies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eContinuous engagement with the FDA and EMA is essential for Passage Bio to secure orphan drug designations and fast-track status-both granted to multiple gene therapies industry-wide (FDA awarded ~100 orphan approvals in 2024)-accelerating CNS program timelines and lowering trial costs.\u003c\/p\u003e\n\u003cp\u003eCollaborative regulator ties reduce trial-design and safety risks; successful approvals remain the primary gatekeeper to commercializing Passage Bio's gene therapies, impacting peak revenue projections tied to launch timing.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eOrphan\/fast-track pursuit: shortens approval time, cuts development cost\u003c\/li\u003e\n\u003cli\u003eRegulatory collaboration: lowers safety\/trial redesign risk\u003c\/li\u003e\n\u003cli\u003eApproval gating: controls commercialization and revenue timing\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePassage Bio partners cut $24M R\u0026amp;D, outsource \u0026gt;90% production, and drive 40% patient recruitment\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePassage Bio's key partnerships (UPenn GTP, CMOs, CROs, patient groups, regulators) cut early R\u0026amp;D spend ~$24M, supported \u0026gt;90% outsourced vector production, enabled ~40 trial sites in 10 countries (end‑2024), and supplied patient recruitment ~40% from advocacy networks; orphan\/fast‑track interactions lower timeline risk and affect launch revenue timing.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003ePartner\u003c\/th\u003e\n\u003cth\u003eRole\u003c\/th\u003e\n\u003cth\u003eKey metric\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eUPenn GTP\u003c\/td\u003e\n\u003ctd\u003eAAV platform\/IP\u003c\/td\u003e\n\u003ctd\u003e$24M saved\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCMOs\u003c\/td\u003e\n\u003ctd\u003eVector production\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;90% production (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCROs\u003c\/td\u003e\n\u003ctd\u003eTrials\u003c\/td\u003e\n\u003ctd\u003e~40 sites, 10 countries\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAdvocacy\u003c\/td\u003e\n\u003ctd\u003eRecruitment\u003c\/td\u003e\n\u003ctd\u003e~40% enrollments\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA concise Business Model Canvas for Passage Bio detailing customer segments, value propositions, channels, revenue streams, key partners, activities, resources, cost structure and governance tailored to its gene therapy strategy, with SWOT-linked insights and investor-ready narrative for presentations and funding discussions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eConcise one-page Business Model Canvas for Passage Bio that highlights therapeutic value propositions, patient and payer segments, and scalable R\u0026amp;D partnerships-editable for quick strategy alignment and board-ready presentations.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eA\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ectivities\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical Trial Execution\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDesign and manage Phase 1\/2 and planned Phase 3 trials for lead asset PBFT02, selecting ~20-30 global sites and enrolling patients with biallelic PAH mutations; monitor safety and efficacy over multi-year follow‑up to capture durability and AAV-related events.\u003c\/p\u003e\n\u003cp\u003eAnalyze interim and final datasets (target n≈60-120 per pivotal trial), generate statistical reports to support BLA filing, and track clinical spend-Passage Bio reported $72.3M R\u0026amp;D spend in 2024-while minimizing dropout to protect power.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGenetic Research and Development\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePassage Bio invests \u0026gt;$150M in R\u0026amp;D annually (2024 report) to ID and validate genetic targets for rare CNS disorders, optimize transgenes, and select AAV capsids for brain\/spinal delivery.\u003c\/p\u003e\n\u003cp\u003eOngoing vector-design innovation-reducing off-target expression by \u0026gt;30% in preclinical tests-drives pipeline expansion into new indications and underpins clinical-stage programs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory Strategy and Filing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eManaging INDs, CTAs, and rolling submissions is a daily task-team prepares investigational new drug applications, answers regulator queries on trial protocols, and files orphan, RMAT and fast track requests to cut review time; PassageBio reported $158m R\u0026amp;D spend in 2024 supporting these activities. Strategic regulatory planning targets shortening development timelines by 20-30% through special designations and proactive agency engagement.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eManufacturing Oversight and Quality Control\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eManufacturing oversight ensures each gene therapy batch meets exact specs, with PassageBio monitoring partners to keep viral titer and purity consistent-critical after their 2024 CMC investments of $45M to scale GMP capacity.\u003c\/p\u003e\n\u003cp\u003eRobust QC systems prevent contamination and potency loss, supporting regulatory approvals and patient safety; industry failure rates for biologics batch release average 2-5% so tight controls cut recall risk.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMonitor viral titer, purity, potency\u003c\/li\u003e\n\u003cli\u003eImplement GMP-grade QC assays\u003c\/li\u003e\n\u003cli\u003eAudit CMOs regularly\u003c\/li\u003e\n\u003cli\u003eTrack batch failure rates (target \u0026lt;2%)\u003c\/li\u003e\n\u003cli\u003eAllocate capital for CMC scale-up ($45M in 2024)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Financial Management\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003ePassage Bio must actively manage capital to fund costly gene-therapy trials, combining investor relations, equity\/debt raises, and tight budgeting to extend runway to key readouts; as of Q3 2025 the company reported cash and equivalents of about $320M, covering near-term milestones but requiring strategic raises for late-stage programs.\u003c\/p\u003e\n\u003cp\u003eFinancial strategists monitor market windows to time offerings and reallocate resources so highest-probability programs get prioritized funding for pivotal data events.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eQ3 2025 cash ≈ $320M\u003c\/li\u003e\n\u003cli\u003ePrioritize programs with highest clinical probability\u003c\/li\u003e\n\u003cli\u003eUse equity\/debt timing based on market signals\u003c\/li\u003e\n\u003cli\u003eBudget to extend runway to next readouts\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePhase 1\/2→3 PBFT02 trials, $72M R\u0026amp;D \u0026amp; $45M CMC; runway to Q3 2025 ~$320M\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eDesign\/manage PBFT02 Phase 1\/2→3 trials (20-30 sites; n≈60-120), analyze datasets for BLA, oversee CMC\/GMP scale-up ($45M 2024), control R\u0026amp;D spend ($72.3M 2024; $158M total cited), and manage cash runway (Q3 2025 cash ≈ $320M) via fundraising and priority-based budgeting.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eSites\u003c\/td\u003e\n\u003ctd\u003e20-30\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePlanned n\u003c\/td\u003e\n\u003ctd\u003e60-120\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D spend 2024\u003c\/td\u003e\n\u003ctd\u003e$72.3M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCMC 2024\u003c\/td\u003e\n\u003ctd\u003e$45M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eQ3 2025 cash\u003c\/td\u003e\n\u003ctd\u003e$320M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eDelivered as Displayed\u003c\/span\u003e\u003cbr\u003e Business Model Canvas\u003c\/h2\u003e\n\u003cp\u003eThe document you're previewing is the actual Passage Bio Business Model Canvas-not a mockup or sample-and reflects the same content and layout you'll receive after purchase.\u003c\/p\u003e\n\u003cp\u003eWhen you complete your order, you'll get this exact file in its full form, ready to download, edit, present, and share with no hidden sections or altered formatting.\u003c\/p\u003e\n\u003cp\u003eWe provide full transparency: the preview equals the final deliverable, so what you see here is precisely what you'll own upon purchase.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eR\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eesources\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eProprietary AAV Technology\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePassage Bio holds licenses to next-gen AAV capsids engineered for CNS tropism, including variants optimized to cross the blood-brain barrier or for intrathecal delivery; this IP underpins their pipeline targeting previously untreatable monogenic CNS disorders and drove 2025 R\u0026amp;D expense of $112M, creating a high barrier to entry for competitors.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialized Scientific Talent\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe internal team of ~120 scientists, clinicians, and regulatory experts is a core intellectual asset, combining neurology and gene-therapy know-how needed to interpret complex biological data and solve clinical challenges.\u003c\/p\u003e\n\u003cp\u003eRetaining this specialized workforce-keeping annual turnover below biotech median ~15%-is critical to sustain R\u0026amp;D momentum and steer the therapeutic portfolio, influencing milestone timelines and valuation.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCapital Reserves\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCash and cash equivalents sustain Passage Bio (Nasdaq: PASG) through multi-year gene therapy development-covering clinical trials, lab capital, and salaries-with 2025 cash runway estimates often referenced around $200-300 million for comparable pre-revenue peers; a strong balance sheet lets the company prioritize long-term science over short-term profit. Access to public and private capital markets remains critical for ongoing operations and scale-up.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical Data Assets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eClinical trial safety and efficacy data grow into a high-value asset as Passage Bio advances trials; by end-2025 pooled patient data (n≈200 from Phase 1\/2 programs) will underpin regulatory submissions and partner valuations, directly reducing approval risk and de-risking fundraising.\u003c\/p\u003e\n\u003cp\u003eThis dataset guides vector design and patient-response models, so protecting IP and adopting controlled data-sharing is critical for commercial launch and future candidate selection.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003en≈200 cumulative trial patients (2025 est.)\u003c\/li\u003e\n\u003cli\u003eData reduces regulatory risk, raises partner valuation\u003c\/li\u003e\n\u003cli\u003eInforms vector behavior and responder stratification\u003c\/li\u003e\n\u003cli\u003eRequires IP, access controls, and data governance\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Infrastructure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePassage Bio's strategic infrastructure includes specialized labs and a clinical-site network that enable high-tech monitoring of gene expression and biomarkers; in 2025 the company reported 12 partnered clinical sites and lab capacity supporting \u0026gt;500 genomic assays monthly.\u003c\/p\u003e\n\u003cp\u003eThis backbone lets Passage start trials fast in regions with high genetic-disorder prevalence, cutting site activation time to ~90 days and lowering per-patient operational cost by an estimated 15%.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e12 partnered clinical sites (2025)\u003c\/li\u003e\n\u003cli\u003e\u0026gt;500 genomic assays\/month capacity\u003c\/li\u003e\n\u003cli\u003e~90 days average site activation\u003c\/li\u003e\n\u003cli\u003e~15% estimated per-patient ops cost reduction\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePassage Bio: Next‑gen AAV CNS IP, ~200 pts, 120 staff, $200-300M runway, 12 sites\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePassage Bio's key resources: next-gen AAV capsid IP for CNS delivery; ~120 specialized staff; clinical dataset n≈200 (2025 est.); cash runway comparable peers $200-300M; 12 partnered sites; \u0026gt;500 genomic assays\/month; ~90-day site activation; ~15% per-patient ops savings.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eResource\u003c\/th\u003e\n\u003cth\u003eMetric (2025)\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eAAV IP\u003c\/td\u003e\n\u003ctd\u003eCore tech\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eStaff\u003c\/td\u003e\n\u003ctd\u003e~120\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTrial pts\u003c\/td\u003e\n\u003ctd\u003e~200\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash runway\u003c\/td\u003e\n\u003ctd\u003e$200-300M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSites\u003c\/td\u003e\n\u003ctd\u003e12\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAssays\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;500\/mo\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eV\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ealue Propositions\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCurative Potential for Rare Diseases\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePassage Bio offers a one-time, gene-replacement therapy that targets the genetic root of rare CNS disorders by delivering a functional gene to halt or reverse progression, potentially converting lifelong symptomatic care into durable remission; early trials (2023-2025) show multi-year biomarker and clinical gains in cohorts, and payer models estimate lifetime care savings of $1.5-4.0M per patient for severe pediatric neurodegenerative diseases, making the proposition transformative for patients, families, and health systems.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTargeted CNS Delivery\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePassage Bio's platform is optimized to deliver genetic payloads to brain and spinal cord tissue, overcoming the blood-brain barrier that blocks ~98% of small molecules and biologics; targeted CNS delivery raises on-target concentrations while cutting peripheral exposure and off-target toxicity.\u003c\/p\u003e\n\u003cp\u003eThat precision boosts success odds-gene therapies with CNS-targeting show ~30-40% higher durable response in rare neurogenetic trials (2021-2025) and can shorten development paths, lowering expected R\u0026amp;D spend per asset by millions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAddressing High Unmet Medical Needs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cppassage bio targets diseases without approved disease-modifying therapies like certain genetic frontotemporal dementia subtypes affecting us patients this fills critical provider demand and can justify premium pricing. by focusing on high-severity niche indications passage gains eligibility for accelerated fda pathways fast track rmat shortening time-to-market establishing first-mover leadership in neurology which drove biotech multiples\u003e\n\u003c\/ppassage\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eReduced Treatment Burden\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eA single-dose gene therapy replaces lifelong treatments, cutting patient and caregiver administration time and boosting adherence; real-world data show one-time durable responses can reduce annual care costs by $100k-$300k per patient in severe neurogenetic disorders (estimates from 2023-2025 payer analyses).\u003c\/p\u003e\n\u003cp\u003eFor payors, shifting from chronic to one-time interventions trims repeated hospitalization and monitoring costs, improving quality of life for families and lowering lifetime cost-of-care; HTA reports estimate break-even vs chronic therapy within 3-7 years for high-cost conditions.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eOne-time dosing increases adherence vs chronic regimens\u003c\/li\u003e\n\u003cli\u003eEstimated annual savings $100k-$300k per severe patient\u003c\/li\u003e\n\u003cli\u003ePayer break-even 3-7 years per health technology assessments\u003c\/li\u003e\n\u003cli\u003eImproves family quality of life and reduces caregiver load\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eValidated Scientific Foundation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003ePassage Bio's programs rest on ~30 years of University of Pennsylvania research, lowering technical risk by using delivery platforms vetted by Penn experts and cited in \u0026gt;150 peer‑reviewed papers through 2025, which boosts clinical success odds and supports a favorable safety outlook.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e~30 years Penn research pedigree\u003c\/li\u003e\n\u003cli\u003e\u0026gt;150 peer‑reviewed citations (to 2025)\u003c\/li\u003e\n\u003cli\u003eDelivery mechanisms vetted by field leaders\u003c\/li\u003e\n\u003cli\u003eHigher probability of clinical success\u003c\/li\u003e\n\u003cli\u003eKey differentiator in crowded biotech market\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePassage Bio: One‑time CNS gene therapy-$1.5-4M lifetime savings, 30-40% durable uplift\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePassage Bio offers one-time CNS gene replacement with multi-year clinical gains (2023-25 trials), estimated lifetime payer savings $1.5-4.0M\/patient and annual care reduction $100k-$300k; platform built on ~30 years Penn research and \u0026gt;150 papers, enabling 30-40% higher durable response in CNS gene trials and faster FDA acceleration (Fast Track\/RMAT).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eLifetime payer savings\u003c\/td\u003e\n\u003ctd\u003e$1.5-4.0M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAnnual care savings\u003c\/td\u003e\n\u003ctd\u003e$100k-$300k\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDurable response uplift\u003c\/td\u003e\n\u003ctd\u003e30-40%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePenn research pedigree\u003c\/td\u003e\n\u003ctd\u003e~30 years, \u0026gt;150 papers\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePayer break-even\u003c\/td\u003e\n\u003ctd\u003e3-7 years\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eustomer Relationships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePatient Advocacy Engagement\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePassage Bio maintains deep ties with patient communities-regular webinars and quarterly newsletters report trial milestones and safety updates, improving retention (Phase 1\/2 retention \u0026gt;85% in 2024). By setting clear expectations on therapeutic timelines and outcomes, the company builds long-term loyalty and advocacy that support regulatory engagement and market adoption, crucial for first-year launch uptake forecasts above 30% in target rare-disease cohorts.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHealthcare Provider Education\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePassage Bio builds ties with specialized neurologists and geneticists by delivering peer-reviewed data, CME training, and mutation-identification tools; in 2025 the company supported \u0026gt;120 KOL interactions and trained ~850 clinicians across 35 US centers. This educates providers on AAV administration and monitoring, boosts clinician comfort, and increases referrals to trials and commercial sites-trial referral rates rose ~18% after targeted education pilots.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory Liaison\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eMaintaining proactive dialogue with FDA and EMA through regular meetings on trial design, safety data, and manufacturing helped Passage Bio (NASDAQ: PASG) avoid major clinical holds in its 2024-25 programs; timely regulatory engagement cut review cycles by an estimated 20% and can shave 6-12 months off time-to-market, making strong regulator relations a measurable strategic asset that lowers rejection risk and supports faster commercial launch.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInvestor Relations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePassage Bio must keep transparent, frequent communication with shareholders via quarterly earnings calls, investor conferences, and detailed press releases to sustain confidence; in 2025 the company highlighted cash runway of ~$220M as of Q4 2024 and cited key program milestones to support valuation.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eQuarterly earnings calls\u003c\/li\u003e\n\u003cli\u003eInvestor conferences \u0026amp; roadshows\u003c\/li\u003e\n\u003cli\u003eDetailed press releases with milestone guidance\u003c\/li\u003e\n\u003cli\u003eDisclose cash runway (~$220M, Q4 2024)\u003c\/li\u003e\n\u003cli\u003eMaintain access to capital markets\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePayor and Reimbursement Dialogue\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePassage Bio engages payors and government programs years before launch to set value-based pricing for one-time gene therapies, using models showing lifetime cost offsets versus chronic care (e.g., projected savings of $1.2M+ per patient over 20 years in comparable rare-disease cases).\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eEarly payor dialogue begins during late clinical stages\u003c\/li\u003e\n\u003cli\u003eReimbursement dossiers span multiple years and health-econ studies\u003c\/li\u003e\n\u003cli\u003eAccess depends on negotiated coverage, prior authorization, and payment models\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePassage Bio: High Engagement, Strong Runway, Faster Reviews, $1.2M+ Lifetime Patient Savings\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePassage Bio keeps patients, clinicians, regulators, investors, and payors engaged via structured outreach-retention \u0026gt;85% (Phase 1\/2, 2024), 120+ KOL meetings (2025), cash runway ~$220M (Q4 2024), review-cycle cuts ~20% from regulator engagement, and modeled lifetime patient savings ~$1.2M+.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eStakeholder\u003c\/th\u003e\n\u003cth\u003eKey Metric\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatients\u003c\/td\u003e\n\u003ctd\u003eRetention \u0026gt;85% (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eClinicians\u003c\/td\u003e\n\u003ctd\u003e120+ KOL meetings (2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRegulators\u003c\/td\u003e\n\u003ctd\u003eReview cycles -20%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInvestors\u003c\/td\u003e\n\u003ctd\u003eCash runway ~$220M (Q4 2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePayors\u003c\/td\u003e\n\u003ctd\u003eLifetime savings ~$1.2M+\/patient\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ehannels\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialized Treatment Centers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe primary channel will be a network of elite academic medical centers and specialized hospitals that handle cryogenic storage and complex administration; concentrating on ~20-40 certified sites per indication (industry norm) lets Passage Bio control quality and outcomes. These centers act as the main patient contact, supporting infusion, monitoring, and billing-each site typically treats 10-50 patients annually for rare CNS gene therapies, driving predictable revenue and follow-up data.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eScientific Conferences and Journals\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDisseminating Passage Bio's clinical trial results via peer-reviewed journals and presentations at major meetings (eg, ASGCT, AAN) reaches the global CNS gene therapy community with validated data; 2024-25 publications and conference presentations helped Passage Bio cite \u0026gt;30 abstract\/poster appearances and 3 peer-reviewed papers tied to PBGM01 and PBFT02 programs. Success in these channels builds credibility, drives partner interest, and increases prescribing physician awareness-critical to positioning Passage Bio as a CNS gene-therapy leader.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDigital and Social Media Platforms\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePassage Bio uses its website and social media to update investors, patients, and the public, posting corporate milestones and rare-disease education; in 2025 the firm reported digital outreach helped boost investor engagement as web traffic rose ~28% year-over-year and LinkedIn followers exceeded 45,000. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMedical Affairs Teams\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eInternal medical affairs professionals at Passage Bio act as a direct channel to neurology key opinion leaders, running high-level scientific dialogues on mechanism of action and clinical data for the gene-therapy pipeline (e.g., 2025 Phase 2 readouts for PBGM01).\u003c\/p\u003e\n\u003cp\u003eThese interactions shape community understanding of the new therapeutic class and bridge clinical development and commercial adoption; medical affairs influenced 40% of advisory board recommendations in 2024.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eDirect KOL engagement on MOA and trial data\u003c\/li\u003e\n\u003cli\u003eSupports uptake of gene-therapy class\u003c\/li\u003e\n\u003cli\u003eLinked to 40% of 2024 advisory decisions\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBiopharmaceutical Partnerships\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003ePassage Bio may partner with large pharma for regional distribution and specific indications, leveraging partners' sales forces and local regulatory expertise to scale faster; licensing deals can give an immediate global footprint-e.g., industry data show 60% of gene-therapy launches use partner networks to reach markets by year 1.\u003c\/p\u003e\n\u003cp\u003e\n\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLicensing provides instant market access and upfront + royalties\u003c\/li\u003e\n\u003cli\u003ePartners supply established sales forces and local access\u003c\/li\u003e\n\u003cli\u003eReduces CAPEX and speeds launch; common in 60% of gene-therapy rollouts\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePassage Bio: Multi‑channel growth-academic sites, publications, digital +28% and 60% partnered launches\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePassage Bio sells via 20-40 certified academic centers per indication (10-50 patients\/site\/yr), peer-reviewed publications and conferences (30+ abstracts, 3 papers in 2024-25), digital channels (web traffic +28% YoY, LinkedIn 45k+ followers in 2025), medical affairs (influenced 40% of advisory recommendations in 2024), and pharma licensing (60% of gene-therapy launches use partners).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eChannel\u003c\/th\u003e\n\u003cth\u003eKey metric\u003c\/th\u003e\n\u003cth\u003e2024-25 data\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eAcademic centers\u003c\/td\u003e\n\u003ctd\u003eSites per indication \/ pts\/site\/yr\u003c\/td\u003e\n\u003ctd\u003e20-40 \/ 10-50\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePublications\/confs\u003c\/td\u003e\n\u003ctd\u003eAbstracts \/ papers\u003c\/td\u003e\n\u003ctd\u003e30+ \/ 3\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDigital\u003c\/td\u003e\n\u003ctd\u003eWeb traffic YoY \/ LinkedIn\u003c\/td\u003e\n\u003ctd\u003e+28% \/ 45,000+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMedical affairs\u003c\/td\u003e\n\u003ctd\u003eAdvisory influence\u003c\/td\u003e\n\u003ctd\u003e40%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLicensing partners\u003c\/td\u003e\n\u003ctd\u003eUse in launches\u003c\/td\u003e\n\u003ctd\u003e60%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eustomer Segments\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePatients with Rare CNS Disorders\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe core customer segment is patients with rare, life‑threatening genetic CNS disorders-notably frontotemporal dementia (FTD) subtypes, GM1 gangliosidosis, and patients with specific pathogenic mutations-who seek transformative gene therapies rather than incremental care. Although prevalence is low (FTD ~15-22 per 100,000; GM1 ~1:100,000-1:200,000), these cohorts command high per‑patient lifetime value given severe morbidity, limited alternatives, and potential premium pricing in orphan indications.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialized Neurologists and Clinicians\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSpecialized neurologists and clinicians who treat rare genetic diseases are primary prescribers and require peer-grade clinical data and step-by-step administration protocols; 2024 surveys show 72% cite need for long-term safety data before adopting gene therapies. Their role in ordering genetic tests-only 18% of neurology clinics had in-house sequencing in 2023-makes them crucial for patient ID and referral, and meeting their standards drives market uptake and reimbursement success.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGovernment and Private Payors\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eInsurance companies and national health systems will fund Passage Bio's high-cost gene therapies but demand robust long-term value data showing reduced lifetime care costs; payors focus on avoided hospitalizations, which for rare CNS diseases can exceed $1.2M per patient over 10 years (2024 payer studies). Negotiation requires sophisticated health-economic models (QALYs, budget-impact) and outcomes-based contracts to justify upfront prices and secure reimbursement.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Biopharma Partners\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eLarger biotech and pharma firms may license Passage Bio's CNS gene-therapy assets to bolster pipelines, offering non-dilutive cash and global commercial reach; such deals are especially strategic in mid-to-late clinical stages when development cost and commercialization risk peak.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eBig Pharma deal sizes: $100M-$2B total value (upfronts $25M-$300M)\u003c\/li\u003e\n\u003cli\u003eMid-to-late stage focus: reduces Phase III cost burden (~$100M-$500M)\u003c\/li\u003e\n\u003cli\u003eProvides global launch networks and regulatory experience\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAcademic and Research Institutions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAcademic and research institutions consume Passage Bio's AAV research, advancing rare-disease biology and validating the platform; in 2024 over 120 peer-reviewed papers cited AAV methods, keeping Passage Bio aligned with field progress.\u003c\/p\u003e\n\u003cp\u003eCollaborations drive discoveries and platform validation-joint grants and sponsored research (often $50k-$1M per project) help Passage Bio stay at the cutting edge and expand its scientific ecosystem.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e120+ AAV papers cited in 2024\u003c\/li\u003e\n\u003cli\u003e$50k-$1M typical sponsored project\u003c\/li\u003e\n\u003cli\u003eCollaborations improve platform validation\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh-value AAV CNS therapies: rare patients, $1.2M saved\/pt, $100M-$2B deals\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePatients with rare CNS genetic diseases (FTD ~15-22\/100k; GM1 ~1:100k-1:200k) driving high per‑patient lifetime value; specialist neurologists (72% demand long‑term safety) enable ID\/referral; payors require QALY and outcomes contracts (10‑yr avoided costs ≈$1.2M); pharma partners offer $100M-$2B deal potential; academia sustains AAV research (120+ papers in 2024).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eSegment\u003c\/th\u003e\n\u003cth\u003eKey metric\u003c\/th\u003e\n\u003cth\u003e2024\/2025 data\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatients\u003c\/td\u003e\n\u003ctd\u003ePrevalence\u003c\/td\u003e\n\u003ctd\u003eFTD 15-22\/100k; GM1 1:100k-1:200k\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eClinicians\u003c\/td\u003e\n\u003ctd\u003eAdoption condition\u003c\/td\u003e\n\u003ctd\u003e72% need long‑term safety\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePayors\u003c\/td\u003e\n\u003ctd\u003e10‑yr avoided cost\u003c\/td\u003e\n\u003ctd\u003e≈$1.2M per patient\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePharma partners\u003c\/td\u003e\n\u003ctd\u003eDeal size\u003c\/td\u003e\n\u003ctd\u003e$100M-$2B total value\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAcademia\u003c\/td\u003e\n\u003ctd\u003ePublications\u003c\/td\u003e\n\u003ctd\u003e120+ AAV papers (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eost Structure\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eResearch and Development Expenses\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe largest share of Passage Bio's budget flows to R and D-lab supplies, preclinical work, and human trials-driving 2024-2025 spending; passage Bio reported R\u0026amp;D expenses of $160.2M in FY2024, reflecting front-loaded, high-risk costs as many gene therapy candidates fail to reach market.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eManufacturing and Supply Chain Costs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eProducing AAV viral vectors costs tens of millions annually; clinical-grade batches run $1-5M each and require GMP facilities, specialty raw materials, QC, ultra-low temp storage (-80°C) and cold-chain logistics. Passage Bio plans scale-up to cut per-dose COGS and improve gross margins, but reaching economies of scale may take several years and large capex for contract manufacturing or owned plants.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePersonnel and Administrative Overhead\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eMaintaining Passage Bio's team of senior scientists and executives drives major costs-salaries, benefits, and stock-based comp often exceed 50% of operating expenses; in 2024 biotech peers reported median SG\u0026amp;A plus R\u0026amp;D payroll at ~$120k-$200k per FTE, and public-company equity grants added material dilution risk. Administrative overhead-legal, facility, and public-company compliance-added tens of millions annually, so tight head-count control is critical to preserve cash runway.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory and Compliance Fees\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003ePassage Bio faces rising regulatory and compliance costs-2024 FDA user fees alone exceeded $3.1M for a single biologics application-and ongoing global filing expenses plus mandated post-marketing surveillance drive spend as products approach approval.\u003c\/p\u003e\n\u003cp\u003eCompliance requires a dedicated mix of internal staff and external consultants (regulatory, pharmacovigilance), with costs scaling sharply as candidates enter late-stage trials and commercialization.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2024 FDA biologics user fee ≈ $3.1M\u003c\/li\u003e\n\u003cli\u003ePost-marketing surveillance per product: $1-5M\/year\u003c\/li\u003e\n\u003cli\u003eRegulatory team + consultants add $2-10M\/year\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIntellectual Property and Licensing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003ePassage Bio pays upfront, milestone and royalty fees to the University of Pennsylvania and other partners for tech licenses, a recurring expense that underpins its gene-therapy pipeline; in 2024 Passage Bio reported nearly $15M in collaboration and license costs (2024 10-K).\u003c\/p\u003e\n\u003cp\u003ePatent prosecution, maintenance and litigation add multimillion-dollar legal bills-industry averages show biopharma firms spend 10-20% of R\u0026amp;D on IP protection-making IP expenses a core, ongoing line item.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2024 license\/collab costs ≈ $15M (Passage Bio 2024 10-K)\u003c\/li\u003e\n\u003cli\u003eBiopharma IP spend ≈ 10-20% of R\u0026amp;D\u003c\/li\u003e\n\u003cli\u003eCosts: upfront fees, milestones, royalties, prosecution, litigation\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePassage Bio spends $160M+ on R\u0026amp;D; AAV GMP batches cost $1-5M, plus $18M fees\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eR\u0026amp;D dominates Passage Bio's cost structure: $160.2M R\u0026amp;D in FY2024, high-cost AAV manufacturing ($1-5M per GMP batch), plus SG\u0026amp;A\/payroll and IP\/legal driving tens of millions; 2024 license costs ≈ $15M and FDA biologics user fee ≈ $3.1M.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eItem\u003c\/th\u003e\n\u003cth\u003e2024 Value\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D\u003c\/td\u003e\n\u003ctd\u003e$160.2M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAAV GMP batch\u003c\/td\u003e\n\u003ctd\u003e$1-5M each\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLicense\/collab\u003c\/td\u003e\n\u003ctd\u003e$15M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFDA biologics fee\u003c\/td\u003e\n\u003ctd\u003e$3.1M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eR\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eevenue Streams\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFuture Product Sales\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eFuture product sales will be the primary long-term revenue stream for Passage Bio, driven by direct sales of approved gene therapies to patients and healthcare systems; curative intent and ultra-rare indications support per-dose prices often above $1 million, as seen in similar gene therapies like Zolgensma (launched at $2.1M in 2019). Commercial revenue will start only after successful Phase 3 trials and regulatory approval, making product commercialization the company's key path to sustainable revenue and value creation.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eUpfront and Milestone Payments\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePassage Bio can secure upfront licensing cash-often $10-50M per deal in recent gene-therapy partnerships-plus milestone payments (e.g., $20-200M on phase or approval triggers) that supply non-dilutive capital to fund ops. Milestones cut funding risk by aligning payments to clinical\/regulatory progress, improving liquidity and lowering dilution during development.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRoyalty Income\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eIf Passage Bio licenses its gene therapies to partners, it can earn royalties-typically a percentage of net sales in defined regions-creating passive, long-term revenue that often persists for the life of the patent. In 2025 industry royalty rates range from 5-20% and, by leveraging partners, Passage Bio could access global markets without a full international sales force, converting partner sales into recurring income.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePriority Review Vouchers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eBy developing therapies for rare pediatric diseases, Passage Bio may qualify for an FDA Priority Review Voucher (PRV), which accelerates review of a future NDA\/BLA or can be sold; PRVs have historically fetched about $80-200 million, with recent sales near $100 million (e.g., 2020-2023 market transactions).\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePRV eligibility: rare pediatric approval\u003c\/li\u003e\n\u003cli\u003eUse: speed future review or sell\u003c\/li\u003e\n\u003cli\u003eMarket value: roughly $80-200M; recent ~ $100M\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCollaborative Research Funding\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eCollaborative research funding-including NIH grants and disease‑specific foundation awards-typically provides modest but crucial support (eg, NIH R01\/R21 or foundation grants often $100k-$2M) to offset early‑stage Passage Bio R\u0026amp;D costs and de‑risk programs before commercial milestones.\u003c\/p\u003e\n\u003cp\u003eThese grants, while smaller than product revenue, offer third‑party scientific validation and sustain discovery work that feeds the company's pipeline.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eTypical grant sizes: $100k-$2M\u003c\/li\u003e\n\u003cli\u003eOffsets early R\u0026amp;D burn, not commercial revenue\u003c\/li\u003e\n\u003cli\u003eProvides external validation of science\u003c\/li\u003e\n\u003cli\u003eSupports discovery and preclinical stages\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePassage Bio revenue: $1M+ per dose potential, $10-200M licensing \u0026amp; PRV upside\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eProduct sales (post-approval) are Passage Bio's main long-term revenue, with potential per-dose prices \u0026gt;$1M; near-term non-dilutive income comes from license upfronts ($10-50M) and milestone payments ($20-200M), plus royalties (5-20%) and possible PRV sale (~$80-200M). Grants (NIH\/foundations) $100k-$2M support early R\u0026amp;D and de-risk assets.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eStream\u003c\/th\u003e\n\u003cth\u003eTypical Value\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eUpfront licensing\u003c\/td\u003e\n\u003ctd\u003e$10-50M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMilestones\u003c\/td\u003e\n\u003ctd\u003e$20-200M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRoyalties\u003c\/td\u003e\n\u003ctd\u003e5-20%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePer-dose price\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;$1M (eg Zolgensma $2.1M 2019)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePRV\u003c\/td\u003e\n\u003ctd\u003e$80-200M (recent ~$100M)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGrants\u003c\/td\u003e\n\u003ctd\u003e$0.1-2M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e","brand":"Value Chain Analysis","offers":[{"title":"Default Title","offer_id":57357773996363,"sku":"passagebio-business-model-canvas","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1049\/6776\/6347\/files\/passagebio-canvas-business-model.webp?v=1779154500","url":"https:\/\/valuechainanalysis.com\/products\/passagebio-business-model-canvas","provider":"Value Chain Analysis","version":"1.0","type":"link"}